KLF9 and diabetes mellitus: Recently, Cui and colleagues demonstrated that KLF9 promotes the expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC1 α) resulting in hepatic gluconeogenesis and suggested that KLF9 may be responsible for the glucocorticoid therapy-induced diabetes [41].